Abstract:Background: Genomic instability of N6-methyladenosine (m 6 A)–related long noncoding RNAs (lncRNAs) plays a pivotal role in the tumorigenesis of lung adenocarcinoma (LUAD). Our study identified a signature of genomic instability of m 6 A-associated lncRNA signature and revealed its prognostic role in LUAD. Methods: We downloaded RNA-sequencing data and somatic mutation data for LUAD from The Cancer Genome Atlas (TCGA) and the GSE102287 dataset from the Gene Expression Omnibus (GEO) database. The “Limma” R package was used to identify a network of regulatory m 6 A-related lncRNAs. We used the Wilcoxon test method to identify genomic-instability–derived m 6 A-related lncRNAs. A competing endogenous RNA (ceRNA) network was constructed to identify the mechanism of the genomic instability of m 6 A-related lncRNAs. Univariate and multivariate Cox regression analyses were performed to construct a prognostic model for internal testing and validation of the prognostic m 6 A-related lncRNAs using the GEO dataset. Performance analysis was conducted to compare our prognostic model with the previously published lncRNA models. The CIBERSORT algorithm was used to explore the relationship of m 6 A-related lncRNAs and the immune microenvironment. Prognostic m 6 A-related lncRNAs in prognosis, the tumor microenvironment, stemness scores, and anticancer drug sensitivity were analyzed to explore the role of prognostic m 6 A-related lncRNAs in LUAD. Results: A total of 42 genomic instability–derived m 6 A-related lncRNAs were differentially expressed between the GS (genomic stable) and GU (genomic unstable) groups of LUAD patients. Four differentially expressed lncRNAs, 17 differentially expressed microRNAs, and 75 differentially expressed mRNAs were involved in the genomic-instability–derived m 6 A-related lncRNA-mediated ceRNA network. A prediction model based on 17 prognostic m 6 A-associated lncRNAs was constructed based on three TCGA datasets (all, training, and testing) and validated in the GSE102287 dataset. Performance comparison analysis showed that our prediction model (area under the curve [AUC] = 0.746) could better predict the survival of LUAD patients than the previously published lncRNA models (AUC = 0.577, AUC = 0.681). Prognostic m 6 A-related-lncRNAs have pivotal roles in the tumor microenvironment, stemness scores, and anticancer drug sensitivity of LUAD. Conclusion: A signature of genomic instability of m 6 A-associated lncRNAs to predict the survival of LUAD patients was validated. The prognostic, immune microenvironment and anticancer drug sensitivity analysis shed new light on the potential novel therapeutic targets in LUAD.

Computational detection of a genome instability‐derived lncRNA signature for predicting the clinical outcome of lung adenocarcinoma

Identification of a Novel Prognostic Signature of Genome Instability-Related LncRNAs in Early Stage Lung Adenocarcinoma

Mutation-Derived Long Noncoding RNA Signature Predicts Survival in Lung Adenocarcinoma

Identification of the Prognostic Significance of Somatic Mutation-Derived LncRNA Signatures of Genomic Instability in Lung Adenocarcinoma

A Somatic Mutation-Derived Lncrna Signature Of Genomic Instability Predicts Prognosis For Patients With Liver Cancer

A genomic instability-associated lncRNA signature for predicting prognosis and biomarkers in lung adenocarcinoma

Multi-Omics Integrative Bioinformatics Analyses Reveal Long Non-coding RNA Modulates Genomic Integrity via Competing Endogenous RNA Mechanism and Serves as Novel Biomarkers for Overall Survival in Lung Adenocarcinoma

Prognostic Value of Genomic Instability of m6A-Related lncRNAs in Lung Adenocarcinoma

Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer

Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma

Development of a Novel Prognostic Signature of Long Non-Coding RNAs in Lung Adenocarcinoma

A Five-Long Non-Coding RNA Signature with the Ability to Predict Overall Survival of Patients with Lung Adenocarcinoma.

Identification of Immune-Associated Lncrnas As a Prognostic Marker for Lung Adenocarcinoma.

Genome instability-derived genes as a novel prognostic signature for lung adenocarcinoma

A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma

Genomic instability-associated lncRNA signature predicts prognosis and distinct immune landscape in gastric cancer

A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma

Development and Validation of an Endoplasmic Reticulum Stress Long Non-Coding RNA Signature for the Prognosis and Immune Landscape Prediction of Patients with Lung Adenocarcinoma

Identification of an Immune-related Seven-lncRNA Signature Predicting Prognosis and Tumor-infiltrating Immune Cells in Lung Adenocarcinoma

Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD

A Novel Model Based on Genomic Instability-Associated Long Non-Coding RNAs for Predicting Prognosis and Response to Immunotherapy in Patients with Lung Adenocarcinoma